BRAF and non-small cell lung carcinoma: The target recommended phase 2 dose (RP2D) of binimetinib for combination studies with targeted agents is 45 mg B.D. Binimetinib in combination with the BRAF inhibitor encorafenib has been approved by the Food and Drug Administration for the use in BRAFV600EMT melanoma and non-small-cell lung cancer (NSCLC) [25, 26].